Clinical Trial Update: Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis [Phase 4]

View source ↗

Summary

Phase 4 trial of obeticholic acid in primary biliary cholangitis was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis
• Liver Cirrhosis

Drugs mentioned

• Obeticholic acid (obeticholic acid)

Snippet

Sponsor: Intercept Pharmaceuticals | Conditions: Liver Cirrhosis, Biliary | Phase 4 | Status: TERMINATED | Results posted: 2023-03-09